"Designing Growth Strategies is in our DNA"

Histone Deacetylase Inhibitors Market Size, Share and Global Trend By Class (Class I HDACs, Class II HDACS, Class III HDACs, Class IV HDACs), Application (Oncology, Neurology), End User (Hospitals, Academic & research institutes, Pharmaceutical companies) and Geography Forecast till 2026

Region : Global | Report ID: FBI100323 | Status : Ongoing

 

KEY MARKET INSIGHTS

Histone deacetylase inhibitor (HDACI) is an enzyme, which inhibits histone deacetylase by removing the acetyl group from n-acetyl lysine amino acid sequence. Histone deacetylase inhibitors have potential applications in diagnosis, treatment and prognosis of cancer. They are also used as a treatment option for haematological malignancies and play important role in epigenetic or non-epigenetic regulation. In March 2017, AMO PHARMA and Ranedis Pharmaceuticals entered into  collaboration to develop RND-001, a histone deacetylase inhibitor used in specific lysosomal storage disorders and neurodegenerative disorders. Recent findings by the researchers suggest that, histone deacetylase inhibitors can be used for the potential multimodal treatment of cachexia.

To gain extensive insights into the market, Request for Customization


Anti-inflammatory and anti-apoptotic properties of histone deacetylase inhibitors can be applied for the treatment of a range of neurological disorders, including multiple sclerosis. Increasing incidence of cancer and neurological disorders, and increasing use of the histone deacetylase inhibitors for the treatment of the disorders related to central nervous system is one of the major factor driving the growth of the global histone deacetylase inhibitors market. Additionally, high investment in the research and development of the cancer treatment, and increased number of collaborations and investments in the histone deacetylase inhibitors manufacturing are some of the factors driving the growth of the global histone deacetylase inhibitors market.


The factor that is expected to inhibit the growth of the market is the lack of favourable reimbursement policies and stringent regulations for the product approval.


Key Players Covered


Some of the major companies that are present in the global histone deacetylase inhibitors market Merck KGaA, Medivir AB, Cetya Therapeutics, BioVision Inc., R&D Systems, Inc., Mirati Therapeutics, Abcam plc., TCI Chemicals (India) Pvt. Ltd., InvivoGen, and other players.


 SEGMENTATION


























  SEGMENTATION



 DETAILS



By Class



·         Class I HDACs


·         Class II HDACS


·         Class III HDACs


·         Class IV HDACs.



By Application



·         Oncology


·         Neurology


·         Others.



By End User



·         Hospitals,


·         Academic & research institutes


·         Pharmaceutical companies


·         Others.



By Geography



·      North America (USA and Canada)


·      Europe (UK, Germany, France, Italy, Spain, Scandinavia and Rest of Europe)


·      Asia Pacific (Japan, China, India, Australia, Southeast Asia and Rest of Asia Pacific)


·      Latin America (Brazil, Mexico and Rest of Latin America)


·      Middle East & Africa (South Africa, GCC and Rest of Middle East & Africa)



                               


At present, cancer accounts for the largest proportion of the market, this is expected to have higher demand in the field of oncology during the forecast period.


Key Insights 



  • Prevalence of Key Disease Conditions (Cancer, Haematology Diseases, etc.)

  • Pipeline Analysis, Key Players


Regional Analysis


Among these regions, North America dominated the global histone deacetylase inhibitors market in 2017. Development of new drugs, rise in prevalence of cancer and neurological disorders, and high acceptance of histone deacetylase inhibitors are expected to drive the market in the region. According to the American Cancer Society, an estimated 12.0% of U.S. women develop breast cancer in their lifetime. Also, in 2015, about 2,300 men in the U.S., were diagnosed with breast cancer. Europe and Asia Pacific are anticipated to have a significant CAGR during the forecast period, due to rise in number of neurological disorder cases, rise in demand for advanced treatment by the patient pool, and rising healthcare expenditure in the region.


Key Industry Developments



  • Huya Bioscience International is currently developing HBI-8000, oral class I selective HDACI.

  • In December 2018, Helsinn Healthcare SA., announced interim data of Phase 2 study evaluating pracinostat, a histone deacetylase inhibitor, in combination with azacitadine for the treatment of patients with IPSS-R high/very high-risk of Myelodysplastic Syndrome (MDS).

  • A research published by the Graduate Institute of Cancer Biology and Drug Discovery Taipei Medical University, Taipei, Taiwan in 2017, signified the novel class IIa-Selective Histone Deacetylase Inhibitors were discovered using an in silico virtual screening approach.

  • In December 2013, Spectrum Pharmaceuticals, Inc., announced submission of new drug application for Belinostat, a novel pan-HDAC inhibitor.


Histone Deacetylase Inhibitors Market Size, Share and Global Industry Trend Forecast till 2026
  • Ongoing
  • 2019
  • 2016-2018

    CHOOSE LICENSE TYPE

  • 4850
    6850
    8850

Personalize this Research

  • Granular Research on Specified Regions or Segments
  • Companies Profiled based on User Requirement
  • Broader Insights Pertaining to a Specific Segment or Region
  • Breaking Down Competitive Landscape as per Your Requirement
  • Other Specific Requirement on Customization

Healthcare Clients

chong-kun-dang
lpsos
Natus-Medical
DAEWOONG
Abbott

Client Testimonials

“We are happy with the professionalism of your in-house research team as well as the quality of your research reports. Looking forward to work together on similar projects”

- One of the Leading Food Companies in Germany

“We appreciate the teamwork and efficiency for such an exhaustive and comprehensive report. The data offered to us was exactly what we were looking for. Thank you!”

- Intuitive Surgical

“I recommend Fortune Business Insights for their honesty and flexibility. Not only that they were very responsive and dealt with all my questions very quickly but they also responded honestly and flexibly to the detailed requests from us in preparing the research report. We value them as a research company worthy of building long-term relationships.”

- Major Food Company in Japan

“Well done Fortune Business Insights! The report covered all the points and was very detailed. Looking forward to work together in the future”

- Ziering Medical

“It has been a delightful experience working with you guys. Thank you Fortune Business Insights for your efforts and prompt response”

- Major Manufacturer of Precision Machine Parts in India

“I had a great experience working with Fortune Business Insights. The report was very accurate and as per my requirements. Very satisfied with the overall report as it has helped me to build strategies for my business”

- Hewlett-Packard

“This is regarding the recent report I bought from Fortune Business insights. Remarkable job and great efforts by your research team. I would also like to thank the back end team for offering a continuous support and stitching together a report that is so comprehensive and exhaustive”

- Global Management Consulting Firm

“Please pass on our sincere thanks to the whole team at Fortune Business Insights. This is a very good piece of work and will be very helpful to us going forward. We know where we will be getting business intelligence from in the future.”

- UK-based Start-up in the Medical Devices Sector

“Thank you for sending the market report and data. It looks quite comprehensive and the data is exactly what I was looking for. I appreciate the timeliness and responsiveness of you and your team.”

- One of the Largest Companies in the Defence Industry
We use cookies to enhance your experience. By continuing to visit this site you agree to our use of cookies . More info.
X